Channel Therapeutics Corporation

OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so

Rapport Therapeutics Inc. charted a path for its initial public offering and executed the IPO according to the plan it laid out for investors, reaping a slight reward on its first day of trading on 7

The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an

Company Changes AGUIAR-LUCANDER , Renee To: Pharmalink AB , CEO (May) From: Omega Fund Management, Partner & COO Phone: +48 8 411 3005 BRUHN , Suzanne, PhD To: Proclara Biosciences , Pres.